Nicholas N. Vahanian

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

Richard Metz, Sonja Rust, James B. DuHadaway et al. · OncoImmunology · 2012 · 377 citations · Full text

Life Sciences, Immunology, Oncology +17

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

Hatem Soliman, Erica L. Jackson, Tony Neuger et al. · Oncotarget · 2014 · 171 citations · Full text

Medicine, Oncology, Pharmacology +7

Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer

Oliver Wildner, John C. Morris, Nicholas N. Vahanian et al. · Gene Therapy · 1999 · 171 citations

Life Sciences, Molecular Biology, Oncology +12

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek et al. · Journal for ImmunoTherapy of Cancer · 2018 · 152 citations · Full text

Medicine, Oncology, Pharmacology +9

A phase I study of indoximod in patients with advanced malignancies

Hatem Soliman, Susan Minton, Hyo S. Han et al. · Oncotarget · 2016 · 144 citations · Full text

Medicine, Oncology, Pharmacology +6